ZymoGenetics Appoints Dennis M. Miller, Ph.D., Senior Vice President, Research and Preclinical Development
SEATTLE--(BUSINESS WIRE)--Sep 18, 2009 - ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that Dennis M. Miller, Ph.D. has been promoted to the position of Senior Vice President of Research and Preclinical Development and will serve as a member of the company's executive management committee.
“Dennis has a deep understanding of the drug discovery and development process and has worked extensively with biologics during his many years in the biopharmaceutical industry. In addition to scientific knowledge, we're fortunate that he has a keen business sense,” said Douglas E. Williams, Chief Executive Officer of ZymoGenetics. “I look forward to working with Dennis as he leads our research efforts going forward.”
Dr. Miller has been with ZymoGenetics since 2005 working in positions within the Research and Development organization. Most recently, he served as Vice President, Preclinical Development. Before joining ZymoGenetics, Dr. Miller worked for Seattle Genetics. He has also worked at Amgen, Nycomed R&D and Sterling Winthrop in a variety of preclinical and clinical development roles, with contributions to a number of marketed products, including interferon alfacon1, palifermin, anakinra and romiplostim. Before entering the biopharmaceutical industry, Dr. Miller completed a post-doctoral fellowship at the University of Washington in the Department of Environmental Health. Dr. Miller received a B.S. in Biochemistry from the University of Rochester and a Ph.D. in Biochemistry from Utah State University.
ZymoGenetics is focused on the creation of novel protein drugs to improve patient care and address unmet medical needs. The company's strategy is to discover, develop and commercialize its products independently, in collaboration with partner companies or through out-licensing. ZymoGenetics developed and markets RECOTHROM® Thrombin, topical (Recombinant), a synthetic version of a human blood-clotting enzyme used to stop bleeding during surgery. The company is developing a proprietary portfolio of immune-based product candidates. PEG-Interferon lambda is a novel type-3 interferon in clinical development for the treatment of chronic hepatitis C infection. Interleukin-21 is a novel cytokine in clinical development for the treatment of metastatic melanoma and renal cell carcinoma. Several other proprietary product candidates are in preclinical development. In addition, ZymoGenetics has licensed rights to multiple clinical and preclinical drug candidates being developed by other companies. For further information, visit www.zymogenetics.com.
Contact: ZymoGenetics, Inc.
Director, Corporate Communications
Susan W. Specht, MBA, 206-442-6592
Posted: September 2009